BRAF and neoplasm: In addition, a BRAF-V600E mutation in the MAPK pathway can lead to the increase of drug resistance in tumor cells [43,44], which is consistent with our results, that is, that the MAPK signaling pathway is enriched in the non-responder (Figure 2C).